TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Patient Selection~* Diagnosis of metastatic stage IIIB/IV lung adenocarcinoma~* Presence of known sensitizing mutations in EGFR TK domain~* Consented to HRPO# 201305031 (Tissue and Blood Acquisition for Genomic Analysis and Collection of Health Information from Patients with Thoracic Malignancies, Suspected -Thoracic Malignancies, or Mesothelioma)~* Treatment with standard of care erlotinib~* At least 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Group Exercise After Hip Replacement Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hip osteoarthritis patients who undergo surgery with total prosthesis at St. Olav's Hospital, Department Orkdal.~* Participants must live in commuting distance from the hospital, as the training is organized as outpatient training~* Participants must be able to take instruction and master the Norwegian language~Exclusion Criteria:~* Patients who experience serious complications after surgery~* if a person has a disease that causes that one can not complete the planned training

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group training on land (Type: ACTIVE_COMPARATOR): Group training in water and on land are carried out by the same principles, which is to improve general function, and to improve function and strength around the operated hip.
- Group training in water (Type: ACTIVE_COMPARATOR): Group training in water and on land are carried out by the same principles, which is to improve general function, and to improve function and strength around the operated hip

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects achieving clinical response (CDAI decrease of at least 100 points) and/or remission (CDAI less than 150) upon completion of treatment in Study CCX114151 or another GSK sponsored induction study~* Written informed consent prior to any CCX114157 specific study procedures~* Females of child-bearing potential must be sexually inactive or commit to use of consistent and correct use of contraceptive methods with a failure rate of less than 1 percent~* Stable doses of Crohn's disease medications~* Subjects on corticosteroids at entry must be willing to undergo corticosteroid dose taper during the study~Exclusion Criteria:~* If female, is pregnant, has a positive pregnancy test or is breast-feeding~* Subjects with known or suspected coeliac disease or a positive screening test (anti-tissue transglutaminase antibodies) should have been excluded from enrolment into the induction studies. Subjects in whom a diagnosis of coeliac disease is subsequently suspected should have this excluded with testing for anti-tissue transglutaminase antibodies prior to enrolment into the maintenance study.~* Known or suspected fixed symptomatic small bowel stricture~* Enterocutaneous, abdominal or pelvic fistulae likely to require surgery during the study period~* Current sepsis or infections requiring intravenous antibiotic therapy for greater than 2 weeks~* Evidence of hepatic dysfunction, viral hepatitis, or liver function abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- GSK1605786A once daily (Type: EXPERIMENTAL): 500 milligrams once daily
- GSK1605786A twice daily (Type: EXPERIMENTAL): 500 milligrams twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The COVID-IYON Study - Study Examining Data Pertaining to Clinical Outcomes and Organisational Responses to the 2020 SARS-CoV-2 Pandemic

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18~2. Informed consent has been obtained.~3. Cytotoxic chemotherapy, targeted anticancer therapy, immunomodulatory anticancer therapy, hormonotherapy, radiotherapy, oncologic surgery, or other anticancer treatment within the last 12 months (ongoing and completed).~4. Tested positive for SARS-CoV-2.~Exclusion Criteria:~There are no exclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Proactive Therapeutic Drug Monitoring Based Adalimumab Therapy Optimization in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of rheumatoid arthritis~* Starting or already being treated with standard dose adalimumab, 40 mg subcutaneously (SQ) every two weeks~* Good medication adherence rate defined as Proportion of Days Covered (PDC) 80% and above~Exclusion Criteria:~* Detectable anti-adalimumab antibodies~* Overlapping immune mediated diseases~* Steroid therapy for more than 2 months prior to study enrollment~* Poor medication adherence rate (PDC \< 80%)~* History of recurrent infection resulting in therapy pause~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TDM based adalimumab dose optimization group (Type: EXPERIMENTAL): Therapeutic drug monitoring (TDM) provides an opportunity for a proactive and individualized therapy optimization based on serum drug concentration and anti-drug antibodies development.
- Standard of care (Type: NO_INTERVENTION): Standard of care practice for RA management is based on disease activity guided therapy adjustments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Contribution of Hypnotic Analgesia to Local Anesthesia During Bronchial Endoscopy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Person who has given oral consent~* Patient having:~  * a bronchial endoscopy for diagnostic purposes,~ * performed on schedule in the Pneumology Department and Intensive Respiratory Care at the Dijon University Hospital~ * regardless of the indication or samples taken during the examination (simple exploration, lavage, biopsies)~Exclusion Criteria:~* Person not affiliated to a national health insurance system~* Person subject to legal protection (curatorship, guardianship)~* Person under judiciary protection~* Non-menopausal woman~* Adult unable or unwilling to consent~* Minor~* Patient who does not speak French~* Patient with severe hearing disorder that make it difficult to perform hypnosis under good conditions~* Patient with psychiatric or neurological disorders such as dementia, psychosis or profound mental retardation~* Severe COPD requiring long-term oxygen therapy at home or with a tracheotomy~* Patient undergoing bronchial endoscopy for the management of acute respiratory distress

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 Hypnosis (Type: EXPERIMENTAL): None
- Group 2 music (Type: ACTIVE_COMPARATOR): None
- Control group (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: PROUD Study - Preventing Opioid Use Disorders

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria Intervention group:~* Prospective study participants undergoing unilateral total hip replacement surgery between the months of February through May, 2021~Inclusion Criteria Control:~* Retrospective controls selected from the Emory Healthcare System Clinical Data Warehouse that underwent unilateral total hip replacement surgery between the months of February through May, 2020~Inclusion Criteria Professional Staff:~* All staff that participate in the implementation of the opioid free surgical protocol.~Exclusion Criteria:~* Participants that do not speak English will not be eligible for participation in the study.~* Individuals less than 18 years of age will not be included for participation in the study.~* Individuals with cognitive impairment or the inability to provide informed consent will not be included in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prospective cases undergoing non-opioid drug regimen (Type: EXPERIMENTAL): Prospective study participants undergoing unilateral total hip replacement surgery and non-opioid drug regimen perioperatively
- Retrospective control underwent opioid drug regimen (Type: NO_INTERVENTION): Retrospective controls that underwent unilateral total hip replacement surgery and used opioid drug regimen perioperatively
- Professional Staff (Type: NO_INTERVENTION): Staff that participate in the implementation of the opioid free surgical protocol will be completing team assessment surveys seeking their opinion about interprofessional teamwork and communication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: NLA101 in Adults Receiving High Dose Chemotherapy for AML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Criteria:~Inclusion Criteria:~* Age ≥ 18 (or legal age of majority for sites outside US).~* Untreated de novo or secondary acute myeloid leukemia (AML), including AML that has progressed from myelodysplastic syndrome (MDS), and histologically documented diagnosis~* Eligible for at least 2 cycles of standard of care AML chemotherapy that will result in moderate to severe myelosuppression and have curative intent~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 or Karnofsky Status of 50 to 100.~* Adequate cardiac, renal, and hepatic functions.~Exclusion Criteria:~* Extramedullary disease in the absence of bone marrow or blood involvement~* Acute promyelocytic leukemia (APL) with PML-RARA~* Prior AML therapy, with the exception of intrathecal chemotherapy or emergent radiation for myeloid sarcoma.~* Concurrent malignancy requiring active treatment with chemotherapy, immunotherapy, or radiation~* Prior allotransplant, including allogeneic hematopoietic cell transplant or solid organ allogeneic transplant~* Known hypersensitivity or history of hypersensitivity to dimethylsulfoxide (DMSO)~* Active/chronic human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Arm (Type: OTHER): The Control Arm will receive standard of care (SOC) chemotherapy without the infusion of NLA101. SOC chemotherapy will be determined by local PI and must be a standard regimen for untreated de novo or secondary AML that will result in moderate to severe myelosuppression and will be given with curative intent.
- Low Dose Arm (Type: EXPERIMENTAL): The Low Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of low-dose NLA101.
- Medium Dose Arm (Type: EXPERIMENTAL): The Medium Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of medium-dose NLA101.
- High Dose Arm (Type: EXPERIMENTAL): The High Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of high-dose NLA101.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Real Time Optical Coherence Tomography (OCT) of Human Tissue

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Women 18 years of age or older~2. Signed ICF~3. Women who have been histologically diagnosed with invasive ductal carcinoma or invasive lobular carcinoma of the breast prior to surgery~4. Planning breast preservation~5. Patients undergoing lumpectomy (partial mastectomy) procedure~Exclusion Criteria:~1. Multicentric disease (histologically diagnosed cancer in two different quadrants of the breast)~2. Neoadjuvant systemic therapy~3. All T4 tumors~4. Previous radiation in the operated breast~5. Prior surgical procedure in the same quadrant~6. Implants in the operated breast~7. Pregnancy~8. Lactation~9. Participating in any other investigational study for either drug or device which can influence collection of valid data under this study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Biliary Interventions in Critically Ill Patients With Secondary Sclerosing Cholangitis (BISCIT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients have to fulfill all of the following inclusion criteria to be eligible for participation in this study:~1. Men, women\*, inter/divers, age ≥18 and ≤ 80 years (conscious or unconscious patients may be included)~2. Signed written informed consent obtained by patient or legal representative in case of unconscious patient~3. Willingness to comply with treatment and follow-up procedures~4. Suspected SSC-CIP = episode of critical illness and intensive care unit treatment \> 3 days within last 12 months~5. SSC-CIP is confirmed by ERC, (if the first ERC is performed at baseline, the patient may be considered as screening failure if the diagnosis is not confirmed)~6. Elevation of bilirubin ≥ 2.5 upper limit of normal (ULN) at Screening~7. Elevation of alkaline phosphatase (AP) or gamma-glutamyl-transferase (GGT) \> 2.5 ULN or elevation of both at Screening~8. \*Women without childbearing potential defined as follows:~   * at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or~  * hysterectomy or uterine agenesis or~  * ≥ 50 years and in postmenopausal state \> 1 year or~  * \< 50 years and in postmenopausal state \> 1 year with serum Follicle Stimulating Hormone (FSH) \> 40 IU/l and serum estrogen \< 30 ng/l or a negative estrogen test, both at screening or~     \*Women of childbearing potential:~  * who are practicing sexual abstinence (periodic abstinence and withdrawal are not acceptable) or~  * who have sexual relationships with female partners only and/or with sterile male partners or~  * who are sexually active with fertile male partner, have a negative pregnancy test during screening and agree to use reliable methods of contraception (failure rate of \< 1% per year) from the time of screening until end of the clinical trial.~Exclusion Criteria:~1. Patient is too unstable to undergo ERC~2. Inclusion in any other intervention trial within the last 30 days~3. Pregnancy or lactation period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- interventional (Type: EXPERIMENTAL): The intervention group undergoes scheduled invasive evaluation of the biliary tract with endoscopic retrograde cholangiography (ERC) with biliary interventions (i.e. therapeutic ERC) every 8 weeks for 6 months.
- control (Type: NO_INTERVENTION): The control group receives non-interventional standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Palifermin on Skin Tumors in Patients Undergoing Bone Marrow Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: receiving bone marrow transplant -~Exclusion Criteria: not receiving other growth factors~-

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: None): Patients receiving palifermin to prevent mucositis from bone marrow transplant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years~* Patients with HCC, NSCLC, RCC or CRC treated with an approved antiangiogenic drug (bevacizumab, sorafenib, sunitinib)\*~* Patients with at least one measurable lesion. Lesions must be measurable by CT-scan or MRI (Magnetic resonance imaging) according to Response Evaluation Criteria in Solid Tumours (RECIST)~Exclusion Criteria:~* Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate birth control measures during the course of the trial. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.~* Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results~* Known or suspected allergy to the investigational agent or any agent given in association with this trial -_\> allergy~* MRI contraindications: implants (pacemaker)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: None): Control group n=20
- 2 (Type: None): investigational group (cancer patients) n=40 patients treated with antiangiogenic agent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy